Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences sBC expense by award type — Performance Share Units (PSUs, $M) ($M)
Form 10-K Note 13 Stock-Based Compensation
Latest, FY2025
33
Period ended Dec 31, 2025
Change on a year earlier
-10.8%
37 in FY2024
History
11 years
Since FY2014
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | SBC expense by award type — Performance Share Units (PSUs, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 33 | -10.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 37 | +15.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 32 | +28.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 25 | +47.1% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 17 | -32.0% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 25 | – | Form 10-K (filed 2023-02-22) ↗ |
| FY2018 | Dec 31, 2018 | 31 | +29.2% | Form 10-K (filed 2019-02-26) ↗ |
| FY2017 | Dec 31, 2017 | 24 | +20.0% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 20 | -50.0% | Form 10-K (filed 2019-02-26) ↗ |
| FY2015 | Dec 31, 2015 | 40 | -29.8% | Form 10-K (filed 2018-02-27) ↗ |
| FY2014 | Dec 31, 2014 | 57 | – | Form 10-K (filed 2017-02-27) ↗ |
Cite this data
StockData. (2026). Gilead Sciences SBC expense by award type — Performance Share Units (PSUs, $M) ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/sbc_psu_exp
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.